Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19)

Authors: Galeotti, C., Kaveri, S. V., and Bayry, J.

Publication : Clin. Transl. Immunology; 9,10:e1198 ; November 2020

Affiliations : Service de Rhumatologie Pédiatrique Centre de Référence des Maladies Auto-Inflammatoires Rares et des Amyloses CHU de Bicêtre le Kremlin Bicêtre France; Institut National de la Santé et de la Recherche Médicale Centre de Recherche des Cordeliers Sorbonne Université, Université de Paris France.

Abstract: Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease-19 (COVID-19). Although placebo-controlled, double-blind randomised clinical trials are lacking, current data from either retrospective, case series or open-label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID-19 patients.